Reversible Inhibitors of Monoamine Antidepressants Market

RIMAs are used as antidepressants. They work by reducing the activity of monoamine oxidase which is a chemical found throughout the body. Monoamine oxidase breaks down noradrenaline (also called norepinephrine) and serotonin and other chemicals made and used by the body and brain. These chemicals are important in emotions and depression.
Reversible Inhibitors of Monoamine Antidepressants Market contains market size and forecasts of Reversible Inhibitors of Monoamine (RIMA) Antidepressants in Global, including the following market information:
Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Reversible Inhibitors of Monoamine (RIMA) Antidepressants market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Nonselective MAO-Ainhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Reversible Inhibitors of Monoamine (RIMA) Antidepressants include Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly& Co., GlaxoSmithKline Plc, H. Lundbeck, Merck, Pfizer and Teva Pharmaceutical Industries Ltd. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Reversible Inhibitors of Monoamine (RIMA) Antidepressants companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Segment Percentages, by Type, 2021 (%)
Nonselective MAO-Ainhibitors
Selective MAO-B inhibitors
Nonselective MAO-B inhibitors
Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Segment Percentages, by Application, 2021 (%)
Depression Treatment
Parkinson's Disease Treatment
Other Therapy
Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Reversible Inhibitors of Monoamine (RIMA) Antidepressants revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Reversible Inhibitors of Monoamine (RIMA) Antidepressants revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Alkermes Plc
Allergan Plc
Bristol Myers Squibb Co.
Eli Lilly& Co.
GlaxoSmithKline Plc
H. Lundbeck
Merck
Pfizer
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Co. Ltd.